Clevidipine

What is Clevidipine?

Clevidipine is an ultra-short-acting dihydropyridine calcium channel blocker administered intravenously. It belongs to a class of medications known for their ability to relax blood vessels, thereby lowering blood pressure. Developed for situations requiring rapid and precise control of hypertension, Clevidipine is distinguished by its quick onset and offset of action, making it an ideal choice in critical care settings. Marketed under the brand name Cleviprex, it is a lipid emulsion formulation, which is important to consider for specific patient populations.

Unlike some other calcium channel blockers, Clevidipine is rapidly metabolized by esterases in the blood and tissues, rather than the liver or kidneys. This unique metabolic pathway contributes to its short half-life and predictable pharmacokinetics, allowing for highly titratable blood pressure management without significant accumulation, even in patients with renal or hepatic impairment.

How Does it Work?

The primary mechanism of action for Clevidipine involves blocking L-type voltage-gated calcium channels. These channels are predominantly found in the arterial vascular smooth muscle cells. By inhibiting calcium influx into these cells, Clevidipine prevents muscle contraction, leading to vasodilation, primarily of the arterioles. This arterial relaxation directly results in a decrease in peripheral vascular resistance, which is a key determinant of blood pressure.

Crucially, Clevidipine exhibits high selectivity for vascular smooth muscle. At therapeutic doses, it has minimal effects on myocardial contractility or heart rate, a significant advantage over some other vasodilators that can cause reflex tachycardia. Its rapid hydrolysis by esterases ensures a very quick elimination from the body, meaning that its effects subside swiftly once the infusion is discontinued. This allows clinicians to maintain tight and responsive control over a patient's blood pressure, adjusting the dose as needed with immediate feedback.

Medical Uses

Clevidipine is specifically indicated for the rapid reduction of blood pressure in clinical situations where intravenous therapy is necessary. Its principal uses include:

• Hypertensive emergencies and urgencies: Conditions characterized by severely elevated blood pressure that poses an immediate threat to organ function or requires prompt lowering to prevent such threats.
• Perioperative hypertension: Managing high blood pressure before, during, or after surgical procedures, where stable blood pressure is crucial for patient safety and surgical outcomes.
• Situations requiring precise and titratable blood pressure control: Its rapid onset and offset make it suitable for patients needing fine-tuned adjustments to their blood pressure levels.

Given its metabolism independent of renal and hepatic function, Clevidipine is often considered a favorable option for patients with kidney or liver impairment who require acute blood pressure management.

Dosage

Clevidipine is administered as a continuous intravenous administration infusion. Dosage must be individualized and titrated carefully to achieve the desired blood pressure reduction while avoiding hypotension. Close monitoring of blood pressure and heart rate is essential during the infusion.

• Initial Dose: Typically, the infusion is started at 1-2 mg/hour.
• Titration: The dose can be doubled every 90 seconds (or more slowly, every 5-10 minutes, depending on the clinical situation) until the target blood pressure is reached.
• Maintenance Dose: Once the desired blood pressure is achieved, the infusion rate should be adjusted to maintain that level.
• Maximum Dose: While the recommended maximum infusion rate is 21 mg/hour, some clinical situations may warrant cautious use of higher doses under strict medical supervision.
• Transition: Once oral antihypertensive therapy can be initiated, Clevidipine should be gradually tapered off, typically by halving the dose every 5-10 minutes.

Due to its lipid emulsion formulation, the maximum recommended duration of Clevidipine infusion is generally 72 hours.

Side Effects

Like all medications, Clevidipine can cause side effects. Most are mild and related to its vasodilatory effects. Common side effects include:

• Headache
• Nausea and vomiting
• Flushing
• Dizziness
• Reflex tachycardia (less common than with other vasodilators due to its vascular selectivity)

More serious, but less common, side effects can include profound hypotension if the dose is not carefully titrated, atrial fibrillation, chest pain, and edema. It is contraindicated in patients with allergies to soy or egg products, as the emulsion contains these ingredients. Patients with defective lipid metabolism, such as those with severe aortic stenosis, should also avoid Clevidipine. Caution is advised in patients with elevated intracranial pressure.

Drug Interactions

Clevidipine's unique metabolism by esterases means it does not interact with the cytochrome P450 enzyme system, which is responsible for metabolizing many other drugs. Therefore, it has a low potential for pharmacokinetic drug interactions with other medications metabolized via this pathway.

However, additive hypotensive effects may occur when Clevidipine is co-administered with other antihypertensive agents. Close monitoring of blood pressure is necessary to prevent excessive hypotension. Due to its lipid emulsion formulation, Clevidipine contributes to the body's lipid load. Therefore, concurrent administration with other intravenous lipid emulsions (e.g., propofol) should be carefully considered to avoid excessive lipid intake, especially in patients with impaired lipid metabolism.

FAQ

What is the main advantage of Clevidipine over other IV antihypertensives?

Its ultra-short acting nature, rapid onset, and rapid offset allow for extremely precise and titratable blood pressure control, making it ideal for acute, critical situations.

Can Clevidipine be used in patients with kidney or liver problems?

Yes, Clevidipine is metabolized by esterases in the blood and tissues, not primarily by the liver or kidneys. This makes it a suitable option for patients with impaired renal or hepatic function.

Is Clevidipine safe for long-term blood pressure management?

No, Clevidipine is designed for acute, short-term blood pressure control in critical settings. It is not intended for chronic management of hypertension.

Why is Clevidipine administered only intravenously?

Due to its rapid metabolism, Clevidipine requires continuous intravenous infusion to maintain therapeutic blood levels and a sustained antihypertensive effect.

What is Cleviprex?

Cleviprex is the brand name under which Clevidipine is marketed.

Products containing Clevidipine are available through trusted online pharmacies. You can browse Clevidipine-based medications at ShipperVIP or Medicenter.

Summary

Clevidipine stands out as a highly effective and versatile intravenous dihydropyridine calcium channel blocker for acute blood pressure management. Its unique pharmacokinetic profile, characterized by rapid onset, precise titratability, and swift offset of action, makes it an invaluable tool in managing hypertensive emergencies, perioperative hypertension, and other critical conditions requiring immediate and fine-tuned control of blood pressure. With its metabolism independent of renal and hepatic function, it offers a favorable safety profile for a broad range of patients, provided contraindications and potential side effects are carefully considered and monitored during its short-term use in critical care settings.